MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bahouth, S. W.
Right arrow Articles by Park, E. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bahouth, S. W.
Right arrow Articles by Park, E. A.

0026-895X/97/040620-10$3.00/0
Copyright © by The American Society for Pharmacology and Experimental Therapeutics
All rights of reproduction in any form reserved.
MOLECULAR PHARMACOLOGY 51:620-629 (1997).

Promoter Analysis of the Rat beta 1-Adrenergic Receptor Gene Identifies Sequences Involved in Basal Expression

Suleiman W. Bahouth, Xiaoli Cui,1 Michael J. Beauchamp, Hiromi Shimomura, Shaji T. George, and Edwards A. Park

Department of Pharmacology, College of Medicine, The University of Tennessee, Memphis, Tennessee 38163 (S.W.B., X.C., M.J.B., E.A.P.), Department of Oral Biochemistry, Nippon Dental University, Niigata, Japan (H.S.), and Inovir Inc., New York, New York 10021 (S.T.G.)

The beta 1-adrenergic receptor (beta 1-AR) mediates several functions of catecholamines in the heart, including the stimulation of heart rate and contractility. The expression of the rat beta 1-AR gene was assessed by transiently transfecting chimeric genes containing the beta 1-AR promoter, driving the luciferase reporter gene into various cell lines. beta 1-AR/luciferase vectors containing 3 kb of the 5'-flanking region and extending to -126 relative to the start site of translation were expressed at high levels in ventricular myocytes, SK-N-MC cells, and HepG2 cells. The addition of 26 nucleotides from -125 to -100 to the -3311 beta 1-AR/luciferase chimeric gene reduced expression in myocytes and SK-N-MC cells while eliminating expression in HepG2 cells. This element is located 125 base-pairs 3' to the transcriptional start site. The mutation of four nucleotides between -121 and -118 diminished the inhibitory effect of this element. The inhibitory activity of the -125 to -100 sequence was completely dependent on promoter context and positioning. In addition to this 3' element, sequences between -3311 and -2740 in the 5'-flanking region of the beta 1-AR gene were required for the full transcriptional suppression. Using DNase I footprinting and gel mobility assays, it was determined that within the 26-bp region, rat heart nuclear proteins bound to two sites between nucleotides -123 and -112 and -106 and -100. Therefore, appropriate basal expression of the beta 1-AR gene involves widely separated sequences 3' and 5' to the transcriptional start site.

Copyright © by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
S. W. Bahouth, M. J. Beauchamp, and K. N. Vu
Reciprocal Regulation of beta 1-Adrenergic Receptor Gene Transcription by Sp1 and Early Growth Response Gene 1: Induction of EGR-1 Inhibits the Expression of the beta 1-Adrenergic Receptor Gene
Mol. Pharmacol., February 1, 2002; 61(2): 379 - 390.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
A. J. Morris and C. C. Malbon
Physiological Regulation of G Protein-Linked Signaling
Physiol Rev, October 1, 1999; 79(4): 1373 - 1430.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics